Directly acting antivirals | German Center for Infection Research

Short description

Direct-acting antivirals (DAAs) are antiviral medications that specifically inhibit proteins of the hepatitis C virus (HCV), thereby preventing its replication.

Synonyms

DAA

Detailed description

DAAs specifically interfere with the replication cycle of the hepatitis C virus (HCV). Depending on the active ingredient, they inhibit different viral proteins that are necessary for the virus to replicate. To treat hepatitis C, several DAAs are typically combined. The therapy is generally well tolerated, often lasts eight to twelve weeks, and can permanently eliminate the virus in the vast majority of treated patients, thus curing hepatitis C.

Jan 2020

Aliment Pharmacol Ther

Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis

Autoren

Ebel F et al.

Aug 2019

Sci Rep

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)

Autoren

Dold L et al.

Goethe University Frankfurt

The associated partners at Goethe University Frankfurt are active in the DZIF research areas Hepatitis and Healthcare…

Hannover - Braunschweig

HepNet Study-House

The HepNet Study-House connects individual study centers in the field of hepatitis research and creates a central platform to conduct clinical studies (Investigator Initiated Trials) and build patient cohorts in the field of viral hepatitis. On the one hand, the Study-House is a contact point for ...

Jun 2018

PLoS One.

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation

Autoren

Grottenthaler JM et al.